Page 23 - Sofinnova Partners News Today

Gide has advised Apollo alongside Paul, Weiss, Rifkind, Wharton & Garrison LLP on the conclusion of a partnership agreement with a view to acquiring a minority equity interest in European venture capital firm Sofinnova Partners, which specialises in life sciences and is based in Paris, London and Milan, and to committing to invest to Sofinnova's investment funds.

/PRNewswire/ -- Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced that company...

Apollo Global Management will take a minority equity stake in European venture capital firm Sofinnova Partners.

Apollo expands its growth ecosystem by acquiring a minority stake in pioneering life sciences venture capital firm and providing up to €1 billion of capital commitments Sofinnova Partners poised

Milan-based NanoPhoria raised €3.5 million in seed financing to advance its pre-clinical stage treatment for heart failureMILAN, ITALY / ACCESSWIRE / May 12, 2022 / Sofinnova Partners, a leading European

Evelyn Stevenson joins as Director of Product Management, Ravi Girdhar as Director of Sales in the EMEA region, and Denise Emsden as Vice-President of People and Organizational Development

The round is led by Sofinnova Partners with the support of Sparta CapitalCo-founder and environmental entrepreneur, Mathieu Flamini, appointed CEO to accelerate the transition towards safer and more sustainable

/PRNewswire/ -- GlycoEra AG announced today the appointment of Ganesh V. Kaundinya, Ph.D. as President and Chief Executive Officer. Dr. Kaundinya has been a...

– Two posters describe features of Catamaran’s CAR-NK platform designed to overcome the immunosuppressive effects of the solid tumor microenvironment –CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat ca...

Press release content from Accesswire. The AP news staff was not involved in its creation.